| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281724 | Clinical Gastroenterology and Hepatology | 2013 | 26 Pages |
Abstract
About two-thirds of patients with fistulizing perianal Crohn's disease had fistula closure, and one-third had fistula recurrence after infliximab initiation. Combination therapy, duration of seton drainage less than 34 weeks, and long-term treatment with infliximab were associated with better outcomes.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Guillaume Bouguen, Laurent Siproudhis, Emmanuel Gizard, Timothée Wallenhorst, Vincent Billioud, Jean-François Bretagne, Marc-André Bigard, Laurent Peyrin-Biroulet,